Mother, 38, who had ovaries removed to beat cancer says she 'wouldn't be here' without son
Stacey Broadmeadow, 38, battled through a rare cancer to have her son Harry - despite her ovaries being removed. The Manchester mother credits her son with saving her life. (Source: the Mail online | Health)
Source: the Mail online | Health - April 7, 2023 Category: Consumer Health News Source Type: news
'I had my ovaries removed to beat cancer': Woman who was down to final egg gives birth against odds
Stacey Broadmeadow's hopes of becoming a mother were shattered after her diagnosis - as the disease had spread to her fallopian tubes and ovaries. (Source: the Mail online | Health)
Source: the Mail online | Health - April 7, 2023 Category: Consumer Health News Source Type: news
Testosterone and Ovarian Stimulation in Transmasculine Patients Testosterone and Ovarian Stimulation in Transmasculine Patients
Is it necessary to discontinue gender-affirming testosterone therapy during ovarian stimulation in transmasculine patients undergoing IVF? This paper presents two case studies.Human Reproduction (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2023 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
Is Any Kind of Baby Powder Safe to Use?
Johnson & Johnson is willing to pay almost $9 billion to settle thousands of lawsuits alleging that its talcum powder caused cancers, the company announced Apr. 4.
The proposal is the latest chapter in a long-running saga related to the company’s use of talc—a naturally occurring mineral that has been linked to cancer—in its baby powder. Johnson & Johnson stopped selling baby powder containing talc in North America in 2020, and last year announced plans to discontinue global use of the mineral and sell only a cornstarch-based baby powder formula. At the time, Johnson & Johnson representatives ...
Source: TIME: Health - April 5, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthscienceclimate Source Type: news
Johnson & Johnson Agrees to Pay $8.9 Billion to Settle Talc Lawsuits
Johnson & Johnson has announced it will pay $8.9 billion to settle tens of thousands of talcum powder lawsuits alleging the pharma giant’s talc products caused cancer.
This announcement comes days after the U.S. Court of Appeals for the 3rd Circuit denied the company’s request to delay a bankruptcy decision for its subsidiary, LTL Management, and ordered a U.S. bankruptcy judge to dismiss the case.
Late Tuesday, LTL Management filed for bankruptcy protection for a second time to seek approval for a reorganization plan that will “equitably and efficiently” resolve litigation, Johnson & Johnson wr...
Source: Asbestos and Mesothelioma News - April 5, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Asbestos Exposure Legal Source Type: news
Johnson & Johnson Proposes Paying $8.9 Billion to Settle Talc Baby Powder Lawsuits
NEW BRUNSWICK, N.J. — Johnson & Johnson is earmarking nearly $9 billion to cover allegations that its baby power containing talc caused cancer, more than quadrupling the amount that the company had previously set aside to pay for its potential liability.
Under a proposal announced Tuesday, a J&J subsidiary will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.
The $8.9 billion that J&J would transfer to the subsidiary, LTL Management, would be payable over the next 25 years. The amount is u...
Source: TIME: Health - April 5, 2023 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized Cancer healthscienceclimate wire Source Type: news
Johnson & Johnson Subsidiary LTL Management LLC ( “LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims
NEW BRUNSWICK, N.J., APRIL 4, 2023, - Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will equitably and efficiently resolve all claims arising from cosmetic talc litigation against the Company and its affiliates in North America. To that end, the Company has agreed to contribute up to a present value of $8.9 billion, payable over 25 years, to resolve all the current and future talc claims, which is an increase of $6.9 billion over the $2 billion previously...
Source: Johnson and Johnson - April 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Breast and ovarian cancer linked to Orkney as women from isles 10 times more likely to develop it
The screening research suggests one in 100 people with grandparents from the islands off Scotland have a mutation of the gene BRCA1, which is commonly linked to breast and ovarian cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2023 Category: Consumer Health News Source Type: news
VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy
(MedPage Today) -- TAMPA, Fla. -- As lines of therapy increased for recurrent ovarian cancer, so did the risk of venous thromboembolism (VTE), a retrospective study showed.
Almost 80% of VTEs occurred in patients who had received three or more... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 30, 2023 Category: Cardiology Source Type: news
Mirvetuximab: Practice Changing for Some Ovarian Cancers Mirvetuximab: Practice Changing for Some Ovarian Cancers
Response rates were superior to those seen with other single agents in patients with platinum-resistant disease and tumors positive for folate receptor alpha.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 30, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
New Role for Olaparib in BRCA Ovarian Cancer in Neoadjuvant Setting New Role for Olaparib in BRCA Ovarian Cancer in Neoadjuvant Setting
Administering olaparib in the neoadjuvant setting resulted in favorable surgical options, manageable adverse events, and positive health outcomes in women with ovarian cancer and germline mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 30, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Novel Strategies Show Winning Potential in Ovarian Cancer
(MedPage Today) -- TAMPA, Fla. -- Adding a T-cell primer to a PD-1 inhibitor led to objective responses in a third of patients with recurrent platinum-refractory/resistant ovarian cancer enrolled in a small preliminary study.
Eight of 24 patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 28, 2023 Category: Hematology Source Type: news
Florida woman, 20, develops ovarian tumor the size of an EXERCISE BALL
Allison Fisher, 20, from Jacksonville, said the tumor was so large that she felt like she was pregnant with ten children. It weighed 104lbs and measured 20inches by 20inches. (Source: the Mail online | Health)
Source: the Mail online | Health - March 28, 2023 Category: Consumer Health News Source Type: news
Ovary Removal When Young Could Raise Parkinson's Risk
MONDAY, March 27, 2023 -- Women who have both of their ovaries removed before age 43 have an increased risk of developing Parkinson ’s disease or parkinsonism, according to a recent study.
This may owe to the sudden loss of estrogen and other... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2023 Category: General Medicine Source Type: news
CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer
(MedPage Today) -- TAMPA, Fla. -- About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 26, 2023 Category: Hematology Source Type: news
